Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

ERG Is a New Predisposition Gene for Bone Marrow Failure and Hematological Malignancy

Blood (2023) 142 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2023-191986

Published: 2023

Journal Articles

Genome-Wide Methylation Sensitive Elements Demarcate Targetable Regulatory Elements for Controllable Gene Activation

Yanjing Vera Liu, Jeremiah Suryatenggara, Hannan Wong, Jing Ping Tang, Hong Kee Tan, Junsu Kwon, Qiling Zhou, Simone Ummarino, Alexander Ebralidze, John G. Doench, Li Chai, Touati Benoukraf, Devendra Hiwase, Daniel Thomas, Annalisa Di Ruscio, Daniel G. Tenen, Mahmoud Adel Bassal

Blood (2023) 142 (Supplement 1): 3647.

https://doi.org/10.1182/blood-2023-182715

Published: 2023

Journal Articles

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Monika Kutyna, Maha M Kamel, David M. Ross, Agnes S. M. Yong, Chun Yew Fong, Chloe Thompson-Peach, Steven W. Lane, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1852.

https://doi.org/10.1182/blood-2023-179706

Published: 2023

Journal Articles

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

Devendra Hiwase, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Daniel Thomas

Blood (2023) 142 (Supplement 1): 1847.

https://doi.org/10.1182/blood-2023-179688

Published: 2023

Journal Articles

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Blood (2023) 142 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2023-187860

Published: 2023

Journal Articles

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

Maymona Abdelmagid, Kaaren K. Reichard, Omer Karrar, Rong He, Patricia Greipp, Rhett Ketterling, Mithun V Shah, Devendra Hiwase, Attilio Orazi, Daniel A. Arber, Naseema Gangat, Ayalew Tefferi

Blood (2023) 142 (Supplement 1): 4214.

https://doi.org/10.1182/blood-2023-183010

Published: 2023

Journal Articles

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

Lih En Hong, Chung Hoow Kok, Monika Kutyna, Joule J Li, Rakchha Chhetri, David M. Ross, Susan Branford, Hamish S Scott, Anna Brown, Christopher Norman Hahn, David T Yeung, Mrinal M. Patnaik, Mithun V Shah, Susanna Proudman, Mihir Wechalekar, Devendra Hiwase

Blood (2023) 142 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2023-190809

Published: 2023

Journal Articles

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Maha M Kamel, Monika Kutyna, David M. Ross, Steven W. Lane, Chloe Thompson-Peach, Chun Yew Fong, Agnes S. M. Yong, David T Yeung, Timothy P Hughes, Devendra Hiwase, Daniel Thomas

Blood (2023) 142 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2023-188340

Published: 2023

Journal Articles

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Blood (2023) 142 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2023-187905

Published: 2023

Journal Articles

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

Blood (2023) 142 (Supplement 1): 3234.

https://doi.org/10.1182/blood-2023-185023

Published: 2023

Journal Articles

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Blood (2023) 141 (9): 1087–1091.

https://doi.org/10.1182/blood.2022018236

Published: 2023

Includes: Supplemental data

Journal Articles

Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis

Alia Cibich, Rakchha Chhetri, Kirsty M. Sharplin, Naranie Shanmuganathan, David T. Yeung, Deepak Singhal, Ashanka Mahilal Beligaswatte, Noemi Horvath, Philip Selby, Leanne Purins, Judith Stevens, Peter G. Bardy, Devendra Hiwase

Blood (2022) 140 (Supplement 1): 4892–4893.

https://doi.org/10.1182/blood-2022-170726

Published: 2022

Journal Articles

High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study

Chong Chyn Chua, Natasha S Anstee, Anoop Kumar Enjeti, Devendra Hiwase, Paula Marlton, Ashish Bajel, Shuh Ying Tan, Edward S. Morris, Chun-Kei-Kris Ma, Carolyn Grove, Julian Cooney, Ashanka Beligaswatte, Rachel M Koldej, Stephen B Ting, Travis Perera, Amanda Johnston, John Reynolds, David Ritchie, Andrew H Wei

Blood (2022) 140 (Supplement 1): 3362–3364.

https://doi.org/10.1182/blood-2022-163084

Published: 2022

Journal Articles

Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1 , GATA2 and DDX41

Anna L. Brown, Claire Homan, Michael W. Drazer, Kai Yu, David Lawrence, Jinghua Feng, Luis Arriola-Martinez, Matthew Pozsgai, Kelsey McNeely, Thuong Ha, Parvathy Venugopal, Peer Arts, Sarah King-Smith, Jesse JC Cheah, Mark Armstrong, Csaba Bödör, Paul Wang, Alan B. Cantor, Mario Cazzola, Erin Degelman, Courtney D. DiNardo, Nicolas Duployez, Remi Favier, Stefan Fröhling, Ana Rio-Machin, Jeffery M. Klco, Alwin Krämer, Mineo Kurokawa, Joanne Lee, Luca Malcovati, Neil V Morgan, Georges Natsoulis, Carolyn Owen, Keyur P. Patel, Claude Preudhomme, Hana Raslova, Hugh Young Rienhoff, Jr., Tim Ripperger, Rachael Schulte, Kiran Tawana, Elvira Deolinda Rodrigues Pereira Velloso, Benedict Yan, Raman Sood, Amy Hsu, Steven M. Holland, Kerry Phillips, Nicola Poplawski, Milena Babic, Erika M Kwon Kim, Andrew H. Wei, Cecily Forsyth, Helen Mar Fan, Ian D Lewis, Julian Cooney, Rachel Susman, Lucy C Fox, Piers Blombery, Deepak Singhal, Devendra Hiwase, Andreas W Schreiber, Christopher N Hahn, Hamish S Scott, Paul P. Liu, Lucy A. Godley

Blood (2022) 140 (Supplement 1): 4030–4033.

https://doi.org/10.1182/blood-2022-167600

Published: 2022

Journal Articles

Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm

Monika M Kutyna, Chung Hoow Kok, Yoon Lim, David Campbell, Sharon Paton, Chloe AL Thompson-Peach, Kelly SY Lim, Timothy Hughes, Sharad Kumar, Daniel Thomas, Stan Gronthos, Devendra Hiwase

Blood (2022) 140 (Supplement 1): 9755–9756.

https://doi.org/10.1182/blood-2022-167994

Published: 2022

Journal Articles

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia - the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials

Blood (2022) 140 (Supplement 1): 2931–2932.

https://doi.org/10.1182/blood-2022-168963

Published: 2022

Journal Articles

In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

Blood (2022) 140 (Supplement 1): 6927–6929.

https://doi.org/10.1182/blood-2022-157634

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Blood (2022) 140 (Supplement 1): 10542–10544.

https://doi.org/10.1182/blood-2022-167098

Published: 2022

Journal Articles

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Blood (2022) 140 (Supplement 1): 6964–6965.

https://doi.org/10.1182/blood-2022-168349

Published: 2022

Journal Articles

Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 6962–6963.

https://doi.org/10.1182/blood-2022-167978

Published: 2022

NARROW

ERG Is a New Predisposition Gene for Bone Marrow Failure and Hematological Malignancy

Genome-Wide Methylation Sensitive Elements Demarcate Targetable Regulatory Elements for Controllable Gene Activation

Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia

Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Multi-Hit TP53 Mutations in Myeloid Neoplasms: Prognostic Impact of Morphologic Subtype Designation and Variant Allele Frequency

High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders

Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

TP53 Variant Allele Frequency and Therapy-Related Setting Independently Predict Survival in Myelodysplastic Syndromes with Del(5q)

TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis

High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study

Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1 , GATA2 and DDX41

Senolytic Therapy Can Reverse Senescent Bone Marrow Stroma of Therapy-Related Myeloid Neoplasm

Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia - the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials

In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

Allogeneic Hematopoietic Stem Cell Transplant Outcomes in Adults with Inherited Myeloid Malignancies

Integrated Personalized Prediction Model Identifies a Subgroup of Wild-Type TP53 therapy-Related Myeloid Neoplasm Patients with Poor Outcome

Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only